Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Clements

Showing results (281-290 of 320) with videos related to

Pageof 32
Sort By:
AIDS Research and Human Retroviruses|December 1, 1994
Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials NetworkM C Keefer, B S Graham, R B Belshe, et al.
The Journal of Infectious Diseases|May 1, 1991
The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and childrenM C Steinhoff, N A Halsey, L F Fries, et al.
Science (New York, N.Y.)|May 3, 2008
Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivationTina M Thornton, Gustavo Pedraza-Alva, Bin Deng, et al.
Journal of Clinical Microbiology|August 1, 1992
Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in childrenR B Belshe, R A Karron, F K Newman, et al.
Clinical and Experimental Immunology|November 1, 1994
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials NetworkG J Gorse, D H Schwartz, B S Graham, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2022
Physicians prescribe fewer analgesics during night shifts than day shiftsShoham Choshen-Hillel, Ido Sadras, Tom Gordon-Hecker, et al.
The Journal of Infectious Diseases|October 1, 1994
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials NetworkB S Graham, G J Gorse, D H Schwartz, et al.
The Western Journal of Medicine|April 1, 1985
Clinical management of field worker organophosphate poisoningJ E Midtling, P G Barnett, M J Coye, et al.
The Journal of Infectious Diseases|March 1, 1993
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials NetworkB S Graham, T J Matthews, R B Belshe, et al.
Vaccine|March 4, 2000
Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adultsI M Gonzalez, R A Karron, M Eichelberger, et al.
Pageof 32

Showing results (281-290 of 320) with videos related to

Sort By:
Pageof 32
AIDS Research and Human Retroviruses|December 1, 1994
Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials NetworkM C Keefer, B S Graham, R B Belshe, et al.
The Journal of Infectious Diseases|May 1, 1991
The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold-adapted, influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine retains partial virulence for infants and childrenM C Steinhoff, N A Halsey, L F Fries, et al.
Science (New York, N.Y.)|May 3, 2008
Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivationTina M Thornton, Gustavo Pedraza-Alva, Bin Deng, et al.
Journal of Clinical Microbiology|August 1, 1992
Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in childrenR B Belshe, R A Karron, F K Newman, et al.
Clinical and Experimental Immunology|November 1, 1994
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials NetworkG J Gorse, D H Schwartz, B S Graham, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2022
Physicians prescribe fewer analgesics during night shifts than day shiftsShoham Choshen-Hillel, Ido Sadras, Tom Gordon-Hecker, et al.
The Journal of Infectious Diseases|October 1, 1994
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials NetworkB S Graham, G J Gorse, D H Schwartz, et al.
The Western Journal of Medicine|April 1, 1985
Clinical management of field worker organophosphate poisoningJ E Midtling, P G Barnett, M J Coye, et al.
The Journal of Infectious Diseases|March 1, 1993
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials NetworkB S Graham, T J Matthews, R B Belshe, et al.
Vaccine|March 4, 2000
Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adultsI M Gonzalez, R A Karron, M Eichelberger, et al.
Pageof 32